Treatment with Verzenio plus endocrine therapy demonstrated a statistically significant and clinically meaningful improvement…
Tag:
Lilly's EBGLYSS®
-
-
Lifestyle & Healthslider
Lilly’s Jaypirca (pirtobrutinib), the first and only approved non-covalent (reversible) BTK inhibitor, met its primary endpoint in a head-to-head Phase 3 trial versus Imbruvica (ibrutinib) in CLL/SLL
by Karine Ayoubby Karine AyoubPirtobrutinib met the primary endpoint of response rate non-inferiority, favoring pirtobrutinib with a nominal…
-
Lifestyle & Healthslider
Lilly’s once-weekly insulin efsitora alfa demonstrated A1C reduction and a safety profile consistent with daily insulin in multiple Phase 3 trials
by Karine Ayoubby Karine AyoubResults from the fixed-dose QWINT-1 study, along with the QWINT-3 and QWINT-4 studies, reinforce…
-
Lifestyle & Healthslider
Lilly’s oral GLP-1, orforglipron, showed compelling efficacy and a safety profile consistent with injectable GLP-1 medicines, in complete Phase 3 results
by Karine Ayoubby Karine AyoubThe investigational once-daily pill lowered A1C by an average of 1.3% to 1.6% across…
-
Lifestyle & Healthslider
Lilly appoints Roberta Marinelli as the new President and General Manager for the Middle East and Türkiye region
by Karine Ayoubby Karine AyoubAppointment of Roberta Marinelli as President and General Manager underscores Lilly’s commitment to bold…
-
Lifestyle & Healthslider
Lilly’s EBGLYSS® (lebrikizumab-Ibkz) single monthly maintenance injection achieved completely clear skin at three years in half of patients with moderate-to-severe atopic dermatitis
by Karine Ayoubby Karine AyoubAmong EBGLYSS Week 16 responders from the monotherapy trials, 50% achieved highest bar of…